Cartesian Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cartesian Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-10.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 51% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 97%
Sales fell 97% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-97% / +79%In 3 years sales changed by -97% while total assets changed by +79%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-17.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+60%Cash, after subtracting all debt, equals 60% of its market value (net cash).
Higher than 80% of Healthcare companies in United States.
Tangible Assets Ratio
52%Of every $100 the company owns, $52 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Cartesian Therapeutics, Inc. made a loss over the last year. Cartesian Therapeutics, Inc. owes $1.39 for every $1 it owns. Cartesian Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCartesian Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.49Cartesian Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$187 MThe total market value of all of Cartesian Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeCartesian Therapeutics, Inc.'s net worth is negative ($125 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.39×Cartesian Therapeutics, Inc. owes $1.39 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneCartesian Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-93%Revenue fell 93% in the year to Dec 2025, and shrank 71% a year on average over 3 years.
Profit growth
LossCartesian Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-4658.6%Cartesian Therapeutics, Inc. lost $4659 for every $100 of revenue.
Cash vs debt
Net cashCartesian Therapeutics, Inc. held $112 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Cartesian Therapeutics, Inc. owe compared with what it owns?
Cartesian Therapeutics, Inc. owes $1.39 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Cartesian Therapeutics, Inc. pay a dividend?
No. Cartesian Therapeutics, Inc. does not currently pay a dividend.
Is Cartesian Therapeutics, Inc.'s revenue growing?
Revenue fell 93% in the year to Dec 2025, and shrank 71% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.